fluorobenzenes has been researched along with Necrosis in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biondi-Zoccai, G; Calcagno, S; Canali, E; Conti, G; Fedele, F; Lucisano, L; Mancone, M; Pennacchi, M; Sardella, G; Stio, RE | 1 |
| Cai, J; Du, R; Gao, P; Leng, WX; Liu, DQ; Ma, L; Wang, QJ; Wu, HM; Ye, P; Zhao, XQ | 1 |
| Badia, T; Bellandi, F; Leoncini, M; Maioli, M; Toso, A; Tropeano, F; Villani, S | 1 |
| de Carvalho, M; Evangelista, T; Ferro, J; Pereira, P | 1 |
| Fiebeler, A; Haller, H; Luft, FC; Menne, J; Mervaala, EM; Muller, DN; Park, JK | 1 |
| Hong, MK; Kang, DH; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, JK | 1 |
| McDaniel, MC; Samady, H | 1 |
| Aiello, VD; Casella Filho, A; Chagas, AC; da Luz, PL; Dourado, PM; Galvao, TF; Landim, MB; Mathias, W; Tsutsui, JM | 1 |
| Arslan, S; Güler, A; Kılıçkaya, O; Onan, B; Oztaş, E; Sahin, MA; Ucak, A; Uysal, B; Yılmaz, AT | 1 |
| Garcia-Garcia, HM; Okamura, T; Serruys, PW; Shin, ES | 1 |
| Calcagno, S; Canali, E; Conti, G; De Carlo, C; Di Roma, A; Donahue, M; Fedele, F; Lucisano, L; Mancone, M; Sardella, G | 1 |
| Egede, R; Hansen, HS; Hansen, KN; Jensen, LO; Junker, A; Thayssen, P | 1 |
| Bigley, A; Marsden, AM; Randall, K; Scott, RC; Westwood, FR | 1 |
| Maslov, LN | 1 |
| Artru, AA; Gurevich, B; Katchko, L; Lam, AM; Merkind, V; Mueller, AL; Shapira, Y; Talmor, D | 1 |
1 review(s) available for fluorobenzenes and Necrosis
| Article | Year |
|---|---|
[Coronary perfusion, necrosis area, pumping function of the myocardium, and cardiac electrical stability following revascularisation of infarction-affected myocardium].
Topics: Aged; Anticholesteremic Agents; C-Reactive Protein; Female; Fluorobenzenes; Heart Rate; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Revascularization; Necrosis; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vascular Endothelial Growth Factor A; Vasodilation | 2007 |
6 trial(s) available for fluorobenzenes and Necrosis
| Article | Year |
|---|---|
Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
Topics: Aged; Angina, Stable; Atorvastatin; Elective Surgical Procedures; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Necrosis; Percutaneous Coronary Intervention; Postoperative Complications; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Early decrease in carotid plaque lipid content as assessed by magnetic resonance imaging during treatment of rosuvastatin.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; China; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Cardiotonic Agents; Clopidogrel; Contrast Media; Coronary Angiography; Creatine Kinase, MB Form; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardium; Necrosis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ticlopidine; Treatment Outcome; Troponin I | 2014 |
Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis.
Topics: Aged; Calcinosis; Coronary Angiography; Coronary Artery Disease; Female; Fibrosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Necrosis; Predictive Value of Tests; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Cardiotonic Agents; Coronary Angiography; Coronary Stenosis; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Necrosis; Percutaneous Coronary Intervention; Premedication; Prospective Studies; Pulse Therapy, Drug; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome | 2013 |
Influence of high-dose lipid lowering treatment compared to low-dose lipid lowering treatment on plaque composition assessed by intravascular ultrasound virtual histology in patients with ST-segment elevation acute myocardial infarction: the VIRHISTAMI tr
Topics: Aged; Cholesterol, LDL; Electrocardiography; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Necrosis; Plaque, Atherosclerotic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2013 |
8 other study(ies) available for fluorobenzenes and Necrosis
| Article | Year |
|---|---|
A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin.
Topics: Aged; Biopsy; Creatine Kinase; Cytoplasm; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inclusion Bodies; Male; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Necrosis; Pain; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Topics: Albuminuria; Angiotensin II; Animals; Blood Pressure; Collagen Type IV; Disease Models, Animal; Dose-Response Relationship, Drug; Fibronectins; Fluorescent Antibody Technique, Indirect; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunohistochemistry; Inflammation; Intercellular Adhesion Molecule-1; Kidney; Kidney Cortex; Kidney Medulla; Male; Monocytes; Necrosis; Neutrophil Infiltration; Nitric Oxide Synthase Type II; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Can statins alter coronary plaque composition assessed by radiofrequency backscatter intravascular ultrasound?
Topics: Calcinosis; Coronary Artery Disease; Fatty Acids, Monounsaturated; Fibrosis; Fluorobenzenes; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Necrosis; Observer Variation; Predictive Value of Tests; Pyrimidines; Radiography; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Echocardiography; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Infarction; Myocardium; Necrosis; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces ischemia/reperfusion-induced spinal cord tissue injury in rats.
Topics: Analysis of Variance; Animals; Aorta, Abdominal; Cytoprotection; Disease Models, Animal; Fluorobenzenes; Glutathione Peroxidase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Motor Activity; Necrosis; Neurologic Examination; Neuroprotective Agents; Pyrimidines; Rats; Rats, Wistar; Reperfusion Injury; Rosuvastatin Calcium; Spinal Cord; Spinal Cord Injuries; Sulfonamides; Superoxide Dismutase; Time Factors | 2011 |
Effect of statins on coronary bifurcation atherosclerosis: an intravascular ultrasound virtual histology study.
Topics: Aged; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Fibrosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Necrosis; Odds Ratio; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Calcification | 2012 |
Rosuvastatin: characterization of induced myopathy in the rat.
Topics: Administration, Oral; Animals; Biomarkers; Body Weight; Creatine Kinase; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Muscular Diseases; Necrosis; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2008 |
Neuroprotective effects of NPS 846, a novel N-methyl-D-aspartate receptor antagonist, after closed head trauma in rats.
Topics: Animals; Body Water; Brain; Brain Edema; Brain Ischemia; Calcium; Cerebral Hemorrhage; Fluorobenzenes; Head Injuries, Closed; Homeostasis; Injections, Intraperitoneal; Injury Severity Score; Magnesium; Necrosis; Neuroprotective Agents; Potassium; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sodium; Specific Gravity; Time Factors; Treatment Outcome | 1998 |